Development of a chimeric c-Src kinase and HDAC inhibitor
Kristin S Ko1, Michael E Steffey, Kristoffer R Brandvold
1Department of Chemistry, University of Michigan, 930 N. University Avenue, Ann Arbor, Michigan 48109, United States.
ACS Medicinal Chemistry Letters
|September 10, 2013
Summary
Researchers developed a novel chimeric inhibitor targeting both c-Src kinase and HDAC. This new compound demonstrates superior efficacy in cancer cell lines compared to separate inhibitors, offering a promising cancer therapy advancement.
Area of Science:
- Medicinal Chemistry
- Oncology
- Molecular Biology
Background:
- Synergistic effects observed between c-Src kinase inhibitors and HDAC inhibitors in cancer treatment.
- Need for more effective therapeutic strategies targeting multiple cancer pathways simultaneously.
Purpose of the Study:
- To design and synthesize the first chimeric inhibitor combining c-Src kinase and HDAC inhibitory activities.
- To evaluate the potency and efficacy of the developed chimeric inhibitor in cancer models.
Main Methods:
- Rational drug design based on observed c-Src kinase and HDAC inhibitor synergy.
- Chemical synthesis and optimization of the chimeric inhibitor (Compound 4).
- In vitro evaluation of inhibitory activity against c-Src kinase and HDAC.
- Assessment of anti-cancer efficacy in various human cancer cell lines.
Main Results:
- Successful development of an optimized chimeric inhibitor (Compound 4) with potent dual activity.
- Compound 4 demonstrated significant anti-cancer efficacy in tested cancer cell lines.
- The chimeric inhibitor showed markedly superior efficacy compared to using discrete c-Src and HDAC inhibitors concurrently.
Conclusions:
- The developed chimeric inhibitor represents a novel and potent therapeutic agent for cancer.
- Dual targeting via a single chimeric molecule is a highly effective strategy for cancer therapy.
- Compound 4 warrants further investigation for its clinical potential in treating various cancers.
Related Concept Videos
00:50Anaphase Promoting Complex
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
02:36Chromatin Immunoprecipitation- ChIP
Chromatin immunoprecipitation, or ChIP, is an antibody-based technique used to identify sites on DNA that bind to transcription factors of interest or histone proteins. It also helps determine the type of histone modifications such as acetylation, phosphorylation, or methylation.
Types of ChIP
ChIP can be divided into two types - X-ChIP and N-ChIP. X-ChIP involves in vivo cross-linking of histones and regulatory proteins to DNA, fragmenting the DNA by sonication, and isolating the protein-DNA...
Types of ChIP
ChIP can be divided into two types - X-ChIP and N-ChIP. X-ChIP involves in vivo cross-linking of histones and regulatory proteins to DNA, fragmenting the DNA by sonication, and isolating the protein-DNA...